{
    "nctId": "NCT04579484",
    "briefTitle": "Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study",
    "officialTitle": "Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Time to treatment failure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Sign written and voluntary informed consent\n* Histological confirmation of advanced ER positive and HER2 negative breast cancer.\n* Adult patients at least 18 years of age\n* ECOG performance status equal to 0 or 1\n* Able to provide written informed consent\n* Must be willing to provide blood for ctDNA analysis on study enrollment and at specified study time points\n* Must be willing and able to perform stool sample collection\n* Patients must be suitable, as per their treating physician, for initiation of first line endocrine therapy with an aromatase inhibitor and a CDK 4/6 inhibitor for metastatic disease\n\nExclusion Criteria:\n\n* Prior treatment with CDK 4/6 inhibitors in the neoadjuvant or adjuvant setting\n* Use of targeted therapies other than endocrine therapies alone in the neoadjuvant or adjuvant setting\n* Relapse on prior endocrine therapy or within 6 months of discontinuation of prior adjuvant endocrine therapy\n* History of inflammatory bowel disease, chronic diarrhea or malabsorption syndromes and significant prior bowel resection as judged by the study investigator\n* Use of immunosuppressants including steroids within the previous 4 weeks of planned Cycle 1 Day 1 treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}